Literature DB >> 19768402

Live attenuated vaccines for pandemic influenza.

Grace L Chen1, Kanta Subbarao.   

Abstract

In this chapter, we will review the development of and clinical experience with the currently licensed seasonal live attenuated influenza vaccines (LAIV) and preclinical studies of H5, H7, and H9 live attenuated pandemic influenza vaccine candidates. Vectored vaccine approaches will not be reviewed in this chapter. Experience with seasonal influenza vaccination has demonstrated the safety and efficacy of LAIV in both children and adults; moreover, cross-protection among antigenically distinct viruses within the same subtype may be induced by LAIV. While clinical studies and further characterization of the immunologic response to avian influenza viruses are still needed, the experience with seasonal LAIV underscores the potential of live attenuated vaccines to play an important role in the event of a pandemic.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19768402     DOI： 10.1007/978-3-540-92165-3_5

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN： 0070-217X            Impact factor:   4.291


  10 in total

1.  Ferretting out the facts behind the H5N1 controversy.

Authors:  Roy D Sleator
Journal:  Bioeng Bugs       Date:  2012-05-01

2.  H5N1 influenza viruses: facts, not fear.

Authors:  Peter Palese; Taia T Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-25       Impact factor: 11.205

3.  H5N2 vaccine viruses on Russian and US live attenuated influenza virus backbones demonstrate similar infectivity, immunogenicity and protection in ferrets.

Authors:  Rita Czakó; Leatrice Vogel; Troy Sutton; Yumiko Matsuoka; Florian Krammer; Zhongying Chen; Hong Jin; Kanta Subbarao
Journal:  Vaccine       Date:  2018-03-01       Impact factor: 3.641

4.  Modifications in the polymerase genes of a swine-like triple-reassortant influenza virus to generate live attenuated vaccines against 2009 pandemic H1N1 viruses.

Authors:  Lindomar Pena; Amy L Vincent; Jianqiang Ye; Janice R Ciacci-Zanella; Matthew Angel; Alessio Lorusso; Philip C Gauger; Bruce H Janke; Crystal L Loving; Daniel R Perez
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

5.  African green monkeys recapitulate the clinical experience with replication of live attenuated pandemic influenza virus vaccine candidates.

Authors:  Yumiko Matsuoka; Amorsolo Suguitan; Marlene Orandle; Myeisha Paskel; Kobporn Boonnak; Donald J Gardner; Friederike Feldmann; Heinz Feldmann; Michael Marino; Hong Jin; George Kemble; Kanta Subbarao
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

6.  Programming the magnitude and persistence of antibody responses with innate immunity.

Authors:  Sudhir Pai Kasturi; Ioanna Skountzou; Randy A Albrecht; Dimitrios Koutsonanos; Tang Hua; Helder I Nakaya; Rajesh Ravindran; Shelley Stewart; Munir Alam; Marcin Kwissa; Francois Villinger; Niren Murthy; John Steel; Joshy Jacob; Robert J Hogan; Adolfo García-Sastre; Richard Compans; Bali Pulendran
Journal:  Nature       Date:  2011-02-24       Impact factor: 49.962

7.  Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP.

Authors:  Gabriel Kristian Pedersen; Thomas Ebensen; Ingrid Hjetland Gjeraker; Signe Svindland; Geir Bredholt; Carlos Alberto Guzmán; Rebecca Jane Cox
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

Review 8.  Exploring the Prospects of Engineered Newcastle Disease Virus in Modern Vaccinology.

Authors:  Muhammad Bashir Bello; Khatijah Yusoff; Aini Ideris; Mohd Hair-Bejo; Abdurrahman Hassan Jibril; Ben P H Peeters; Abdul Rahman Omar
Journal:  Viruses       Date:  2020-04-16       Impact factor: 5.048

9.  Molecular signature of high yield (growth) influenza a virus reassortants prepared as candidate vaccine seeds.

Authors:  Manojkumar Ramanunninair; Jianhua Le; Shiroh Onodera; Andrew A Fulvini; Barbara A Pokorny; Jeanmarie Silverman; Rene Devis; Jennifer M Arroyo; Yu He; Alex Boyne; Jayati Bera; Rebecca Halpin; Erin Hine; David J Spiro; Doris Bucher
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

Review 10.  Considerations for setting occupational exposure limits for novel pharmaceutical modalities.

Authors:  Jessica C Graham; Jedd Hillegass; Gene Schulze
Journal:  Regul Toxicol Pharmacol       Date:  2020-11-02       Impact factor: 3.271
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.